Drew Ranieri
Stock Analyst at Morgan Stanley
(1.26)
# 3,716
Out of 5,150 analysts
170
Total ratings
45.65%
Success rate
-11.43%
Average return
Main Sectors:
Stocks Rated by Drew Ranieri
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SIBN SI-BONE | Maintains: Overweight | $20 → $23 | $14.71 | +56.36% | 16 | Dec 2, 2025 | |
| GMED Globus Medical | Maintains: Overweight | $70 → $100 | $90.46 | +10.55% | 14 | Dec 2, 2025 | |
| ATEC Alphatec Holdings | Maintains: Equal-Weight | $16 → $21 | $13.00 | +61.54% | 11 | Nov 10, 2025 | |
| ORGO Organogenesis Holdings | Maintains: Equal-Weight | $4 → $6 | $2.87 | +109.06% | 4 | Mar 5, 2025 | |
| SYK Stryker | Upgrades: Overweight | $370 → $445 | $381.89 | +16.53% | 9 | Dec 2, 2024 | |
| IART Integra LifeSciences Holdings | Maintains: Underweight | $24 → $27 | $10.39 | +159.87% | 15 | Jul 15, 2024 | |
| TMCI Treace Medical Concepts | Maintains: Equal-Weight | $5.5 → $8 | $1.47 | +444.22% | 12 | Jul 15, 2024 | |
| STVN Stevanato Group | Maintains: Equal-Weight | $26 → $22 | $17.50 | +25.71% | 16 | Jul 15, 2024 | |
| NPCE NeuroPace | Maintains: Equal-Weight | $9.5 → $8 | $13.95 | -42.65% | 13 | Jul 15, 2024 | |
| OM Outset Medical | Maintains: Equal-Weight | $75 → $83 | $3.53 | +2,237.11% | 10 | Dec 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $42 → $38 | $28.43 | +33.66% | 9 | Nov 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $88 → $96 | $64.67 | +48.45% | 10 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $28 → $26 | $13.88 | +87.32% | 8 | May 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $290 → $295 | $171.49 | +72.02% | 2 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $236 → $280 | $119.18 | +134.94% | 5 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $11 → $5 | $8.47 | -40.97% | 6 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $72 → $70 | $19.03 | +267.84% | 4 | Oct 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $325 → $300 | $501.18 | -40.14% | 6 | Apr 25, 2022 |
SI-BONE
Dec 2, 2025
Maintains: Overweight
Price Target: $20 → $23
Current: $14.71
Upside: +56.36%
Globus Medical
Dec 2, 2025
Maintains: Overweight
Price Target: $70 → $100
Current: $90.46
Upside: +10.55%
Alphatec Holdings
Nov 10, 2025
Maintains: Equal-Weight
Price Target: $16 → $21
Current: $13.00
Upside: +61.54%
Organogenesis Holdings
Mar 5, 2025
Maintains: Equal-Weight
Price Target: $4 → $6
Current: $2.87
Upside: +109.06%
Stryker
Dec 2, 2024
Upgrades: Overweight
Price Target: $370 → $445
Current: $381.89
Upside: +16.53%
Integra LifeSciences Holdings
Jul 15, 2024
Maintains: Underweight
Price Target: $24 → $27
Current: $10.39
Upside: +159.87%
Treace Medical Concepts
Jul 15, 2024
Maintains: Equal-Weight
Price Target: $5.5 → $8
Current: $1.47
Upside: +444.22%
Stevanato Group
Jul 15, 2024
Maintains: Equal-Weight
Price Target: $26 → $22
Current: $17.50
Upside: +25.71%
NeuroPace
Jul 15, 2024
Maintains: Equal-Weight
Price Target: $9.5 → $8
Current: $13.95
Upside: -42.65%
Outset Medical
Dec 4, 2023
Maintains: Equal-Weight
Price Target: $75 → $83
Current: $3.53
Upside: +2,237.11%
Nov 2, 2023
Maintains: Overweight
Price Target: $42 → $38
Current: $28.43
Upside: +33.66%
May 12, 2023
Maintains: Equal-Weight
Price Target: $88 → $96
Current: $64.67
Upside: +48.45%
May 4, 2023
Maintains: Underweight
Price Target: $28 → $26
Current: $13.88
Upside: +87.32%
Feb 3, 2023
Maintains: Overweight
Price Target: $290 → $295
Current: $171.49
Upside: +72.02%
Jan 6, 2023
Maintains: Equal-Weight
Price Target: $236 → $280
Current: $119.18
Upside: +134.94%
Nov 10, 2022
Maintains: Overweight
Price Target: $11 → $5
Current: $8.47
Upside: -40.97%
Oct 11, 2022
Maintains: Overweight
Price Target: $72 → $70
Current: $19.03
Upside: +267.84%
Apr 25, 2022
Maintains: Equal-Weight
Price Target: $325 → $300
Current: $501.18
Upside: -40.14%